nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—Raltitrexed—Methotrexate—esophageal cancer	0.0556	1	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—KRT19—esophageal cancer	0.0266	0.0548	CbGpPWpGaD
Fluocinolone Acetonide—Ear discomfort—Capecitabine—esophageal cancer	0.0265	0.078	CcSEcCtD
Fluocinolone Acetonide—Amcinonide—ANXA1—esophageal cancer	0.0219	0.362	CrCbGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—TAGLN—esophageal cancer	0.021	0.0431	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—ADP signalling through P2Y purinoceptor 1—GNG7—esophageal cancer	0.0158	0.0324	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—KRT17—esophageal cancer	0.0157	0.0324	CbGpPWpGaD
Fluocinolone Acetonide—Telangiectasia—Methotrexate—esophageal cancer	0.0137	0.0404	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signal amplification—GNG7—esophageal cancer	0.0133	0.0273	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS1—esophageal cancer	0.0114	0.0234	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—ANXA1—esophageal cancer	0.0112	0.0229	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.0109	0.0224	CbGpPWpGaD
Fluocinolone Acetonide—Taste metallic—Methotrexate—esophageal cancer	0.0102	0.03	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—NR1I2—esophageal cancer	0.00986	0.0203	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CRTC1—esophageal cancer	0.00873	0.018	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALDOB—esophageal cancer	0.00782	0.0161	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.00779	0.016	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—KRT14—esophageal cancer	0.00769	0.0158	CbGpPWpGaD
Fluocinolone Acetonide—Leukoderma—Methotrexate—esophageal cancer	0.0076	0.0224	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00756	0.0155	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—bronchus—esophageal cancer	0.00753	0.129	CbGeAlD
Fluocinolone Acetonide—Impaired healing—Methotrexate—esophageal cancer	0.00747	0.022	CcSEcCtD
Fluocinolone Acetonide—Abscess—Cisplatin—esophageal cancer	0.00744	0.0219	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MMP14—esophageal cancer	0.00743	0.0153	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—smooth muscle tissue—esophageal cancer	0.00737	0.126	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—LGALS3—esophageal cancer	0.00736	0.0152	CbGpPWpGaD
Fluocinolone Acetonide—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.0073	0.0215	CcSEcCtD
Fluocinolone Acetonide—Visual acuity reduced—Capecitabine—esophageal cancer	0.0073	0.0215	CcSEcCtD
Fluocinolone Acetonide—Rhinorrhoea—Cisplatin—esophageal cancer	0.00727	0.0214	CcSEcCtD
Fluocinolone Acetonide—Infection—Carboplatin—esophageal cancer	0.00712	0.021	CcSEcCtD
Fluocinolone Acetonide—Dexamethasone—ANXA1—esophageal cancer	0.00688	0.114	CrCbGaD
Fluocinolone Acetonide—PLA2G4A—trachea—esophageal cancer	0.00676	0.116	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Opioid Signalling—PDE4D—esophageal cancer	0.00647	0.0133	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00643	0.0132	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet homeostasis—GNG7—esophageal cancer	0.00634	0.013	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX1—esophageal cancer	0.00633	0.013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Opioid Signalling—GNG7—esophageal cancer	0.00615	0.0127	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Carboplatin—esophageal cancer	0.00613	0.0181	CcSEcCtD
Fluocinolone Acetonide—Wheezing—Cisplatin—esophageal cancer	0.00572	0.0169	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Carboplatin—esophageal cancer	0.00566	0.0167	CcSEcCtD
Fluocinolone Acetonide—Otitis media—Capecitabine—esophageal cancer	0.00558	0.0164	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.00543	0.016	CcSEcCtD
Fluocinolone Acetonide—Rhinorrhoea—Capecitabine—esophageal cancer	0.00536	0.0158	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—NOS2—esophageal cancer	0.00524	0.0108	CbGpPWpGaD
Fluocinolone Acetonide—Folliculitis—Methotrexate—esophageal cancer	0.00514	0.0152	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—SOX2—esophageal cancer	0.00513	0.0106	CbGpPWpGaD
Fluocinolone Acetonide—Eye irritation—Capecitabine—esophageal cancer	0.00508	0.015	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—esophageal cancer	0.005	0.0103	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—neck—esophageal cancer	0.0049	0.0838	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—lung—esophageal cancer	0.00486	0.0831	CbGeAlD
Fluocinolone Acetonide—SERPINA6—lung—esophageal cancer	0.00484	0.0828	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.00481	0.00989	CbGpPWpGaD
Fluocinolone Acetonide—Herpes simplex—Capecitabine—esophageal cancer	0.00471	0.0139	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Capecitabine—esophageal cancer	0.00471	0.0139	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.0046	0.00946	CbGpPWpGaD
Fluocinolone Acetonide—Cataract—Capecitabine—esophageal cancer	0.00456	0.0134	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Capecitabine—esophageal cancer	0.00439	0.013	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—esophageal cancer	0.00436	0.00897	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—SFN—esophageal cancer	0.00431	0.00888	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—SFN—esophageal cancer	0.00428	0.0088	CbGpPWpGaD
Fluocinolone Acetonide—Abscess—Methotrexate—esophageal cancer	0.00408	0.012	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Capecitabine—esophageal cancer	0.00401	0.0118	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—esophageal cancer	0.00385	0.00793	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PTPN2—esophageal cancer	0.00383	0.00788	CbGpPWpGaD
Fluocinolone Acetonide—Nasopharyngitis—Cisplatin—esophageal cancer	0.00382	0.0113	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.00373	0.00768	CbGpPWpGaD
Fluocinolone Acetonide—Prednisolone—CYP2A6—esophageal cancer	0.00371	0.0612	CrCbGaD
Fluocinolone Acetonide—Ear pain—Capecitabine—esophageal cancer	0.00369	0.0109	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CYP26A1—esophageal cancer	0.00369	0.00758	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PFN1—esophageal cancer	0.00361	0.00742	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CAPZA1—esophageal cancer	0.0036	0.0074	CbGpPWpGaD
Fluocinolone Acetonide—Gastroenteritis—Capecitabine—esophageal cancer	0.00356	0.0105	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Methotrexate—esophageal cancer	0.00351	0.0103	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Capecitabine—esophageal cancer	0.00349	0.0103	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—HIF1A—esophageal cancer	0.00347	0.00713	CbGpPWpGaD
Fluocinolone Acetonide—Betamethasone—CYP19A1—esophageal cancer	0.00346	0.0571	CrCbGaD
Fluocinolone Acetonide—NR3C1—epithelium—esophageal cancer	0.00333	0.057	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—lymph node—esophageal cancer	0.00332	0.0568	CbGeAlD
Fluocinolone Acetonide—NR3C1—bronchus—esophageal cancer	0.00328	0.0562	CbGeAlD
Fluocinolone Acetonide—Dexamethasone—NOS2—esophageal cancer	0.00322	0.0532	CrCbGaD
Fluocinolone Acetonide—NR3C1—smooth muscle tissue—esophageal cancer	0.00321	0.055	CbGeAlD
Fluocinolone Acetonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—esophageal cancer	0.00318	0.00655	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—NOS2—esophageal cancer	0.00315	0.00649	CbGpPWpGaD
Fluocinolone Acetonide—Pain in extremity—Capecitabine—esophageal cancer	0.00315	0.00929	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Capecitabine—esophageal cancer	0.00315	0.00929	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00296	0.00609	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—trachea—esophageal cancer	0.00295	0.0504	CbGeAlD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—SMAD4—esophageal cancer	0.00293	0.00602	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—CFL1—esophageal cancer	0.00292	0.00602	CbGpPWpGaD
Fluocinolone Acetonide—Connective tissue disorder—Cisplatin—esophageal cancer	0.00291	0.00857	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.0029	0.00596	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—MYC—esophageal cancer	0.00286	0.00588	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Cisplatin—esophageal cancer	0.00285	0.0084	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—CASP8—esophageal cancer	0.00285	0.00585	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Circadian Clock—HIF1A—esophageal cancer	0.00284	0.00584	CbGpPWpGaD
Fluocinolone Acetonide—Nasopharyngitis—Capecitabine—esophageal cancer	0.00282	0.00831	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Cisplatin—esophageal cancer	0.00276	0.00815	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet homeostasis—NOS2—esophageal cancer	0.00276	0.00568	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—GNG7—esophageal cancer	0.00276	0.00567	CbGpPWpGaD
Fluocinolone Acetonide—Dexamethasone—CYP1B1—esophageal cancer	0.00274	0.0452	CrCbGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00273	0.00562	CbGpPWpGaD
Fluocinolone Acetonide—Influenza—Capecitabine—esophageal cancer	0.00272	0.00803	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Cisplatin—esophageal cancer	0.00267	0.00786	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00264	0.00543	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—ABL1—esophageal cancer	0.00263	0.0054	CbGpPWpGaD
Fluocinolone Acetonide—Alopecia—Cisplatin—esophageal cancer	0.00261	0.0077	CcSEcCtD
Fluocinolone Acetonide—Erythema—Cisplatin—esophageal cancer	0.00257	0.00759	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Cisplatin—esophageal cancer	0.00257	0.00759	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD4—esophageal cancer	0.00255	0.00524	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.00254	0.00522	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—digestive system—esophageal cancer	0.00254	0.0434	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—NOS3—esophageal cancer	0.00254	0.00522	CbGpPWpGaD
Fluocinolone Acetonide—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00253	0.00746	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Methotrexate—esophageal cancer	0.00248	0.0073	CcSEcCtD
Fluocinolone Acetonide—Fluticasone furoate—ABCB1—esophageal cancer	0.00245	0.0405	CrCbGaD
Fluocinolone Acetonide—Infestation NOS—Capecitabine—esophageal cancer	0.00243	0.00716	CcSEcCtD
Fluocinolone Acetonide—Infestation—Capecitabine—esophageal cancer	0.00243	0.00716	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Cisplatin—esophageal cancer	0.00243	0.00715	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—CREBBP—esophageal cancer	0.00239	0.00491	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—BAX—esophageal cancer	0.00238	0.00491	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—ATP1B2—esophageal cancer	0.00238	0.0049	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—HIF1A—esophageal cancer	0.00234	0.00482	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.00232	0.00477	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Circadian Clock—CREBBP—esophageal cancer	0.00232	0.00477	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00231	0.00475	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.00229	0.00472	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—HSPA5—esophageal cancer	0.00225	0.00462	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet homeostasis—NOS3—esophageal cancer	0.00222	0.00456	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.00221	0.00454	CbGpPWpGaD
Fluocinolone Acetonide—Rhinitis—Capecitabine—esophageal cancer	0.00219	0.00644	CcSEcCtD
Fluocinolone Acetonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—esophageal cancer	0.00217	0.00446	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—NOTCH1—esophageal cancer	0.00216	0.00444	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—DOCK2—esophageal cancer	0.00215	0.00443	CbGpPWpGaD
Fluocinolone Acetonide—Connective tissue disorder—Capecitabine—esophageal cancer	0.00214	0.00631	CcSEcCtD
Fluocinolone Acetonide—Dexamethasone—ABCC2—esophageal cancer	0.00214	0.0353	CrCbGaD
Fluocinolone Acetonide—NR3C1—lung—esophageal cancer	0.00212	0.0362	CbGeAlD
Fluocinolone Acetonide—Dexamethasone—CYP2A6—esophageal cancer	0.00211	0.0349	CrCbGaD
Fluocinolone Acetonide—Oedema—Cisplatin—esophageal cancer	0.0021	0.00619	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Capecitabine—esophageal cancer	0.0021	0.00619	CcSEcCtD
Fluocinolone Acetonide—Infection—Cisplatin—esophageal cancer	0.00209	0.00615	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Cisplatin—esophageal cancer	0.00206	0.00607	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00205	0.00422	CbGpPWpGaD
Fluocinolone Acetonide—Eye disorder—Capecitabine—esophageal cancer	0.00204	0.006	CcSEcCtD
Fluocinolone Acetonide—Dexamethasone—CYP19A1—esophageal cancer	0.00201	0.0332	CrCbGaD
Fluocinolone Acetonide—Mediastinal disorder—Capecitabine—esophageal cancer	0.00196	0.00579	CcSEcCtD
Fluocinolone Acetonide—Methylprednisolone—ABCB1—esophageal cancer	0.00196	0.0323	CrCbGaD
Fluocinolone Acetonide—Triamcinolone—PTGS2—esophageal cancer	0.00194	0.032	CrCbGaD
Fluocinolone Acetonide—Alopecia—Capecitabine—esophageal cancer	0.00193	0.00568	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00191	0.00564	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Capecitabine—esophageal cancer	0.00191	0.00563	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Capecitabine—esophageal cancer	0.0019	0.00559	CcSEcCtD
Fluocinolone Acetonide—Erythema—Capecitabine—esophageal cancer	0.0019	0.00559	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00188	0.00555	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.00187	0.00385	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PFN1—esophageal cancer	0.00186	0.00383	CbGpPWpGaD
Fluocinolone Acetonide—Dysgeusia—Capecitabine—esophageal cancer	0.00186	0.00548	CcSEcCtD
Fluocinolone Acetonide—Back pain—Capecitabine—esophageal cancer	0.00184	0.00541	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00181	0.00535	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.00181	0.00373	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.00181	0.00373	CbGpPWpGaD
Fluocinolone Acetonide—Infestation—Methotrexate—esophageal cancer	0.00181	0.00533	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Methotrexate—esophageal cancer	0.00181	0.00533	CcSEcCtD
Fluocinolone Acetonide—Pain—Cisplatin—esophageal cancer	0.0018	0.0053	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Capecitabine—esophageal cancer	0.00179	0.00527	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.00171	0.00353	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Capecitabine—esophageal cancer	0.00171	0.00503	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—esophageal cancer	0.0017	0.0035	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—esophageal cancer	0.00168	0.00347	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CDKN2A—esophageal cancer	0.00167	0.00345	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Cisplatin—esophageal cancer	0.00166	0.0049	CcSEcCtD
Fluocinolone Acetonide—Cough—Capecitabine—esophageal cancer	0.00166	0.00488	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—EGFR—esophageal cancer	0.00164	0.00338	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—EP300—esophageal cancer	0.00163	0.00335	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Capecitabine—esophageal cancer	0.00162	0.00476	CcSEcCtD
Fluocinolone Acetonide—Betamethasone—PTGS2—esophageal cancer	0.00159	0.0262	CrCbGaD
Fluocinolone Acetonide—NR3C1—Circadian Clock—EP300—esophageal cancer	0.00158	0.00325	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Methotrexate—esophageal cancer	0.00156	0.00461	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.00156	0.00321	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Capecitabine—esophageal cancer	0.00155	0.00456	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Cisplatin—esophageal cancer	0.00155	0.00456	CcSEcCtD
Fluocinolone Acetonide—Infection—Capecitabine—esophageal cancer	0.00154	0.00454	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—esophageal cancer	0.00152	0.00313	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Capecitabine—esophageal cancer	0.00152	0.00448	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Methotrexate—esophageal cancer	0.00152	0.00447	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CFL1—esophageal cancer	0.00151	0.0031	CbGpPWpGaD
Fluocinolone Acetonide—Mediastinal disorder—Methotrexate—esophageal cancer	0.00146	0.00431	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00145	0.00299	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—lymph node—esophageal cancer	0.00145	0.0248	CbGeAlD
Fluocinolone Acetonide—Diarrhoea—Cisplatin—esophageal cancer	0.00144	0.00424	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Methotrexate—esophageal cancer	0.00143	0.00423	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—HIF1A—esophageal cancer	0.00143	0.00293	CbGpPWpGaD
Fluocinolone Acetonide—Mental disorder—Methotrexate—esophageal cancer	0.00142	0.00419	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—GNG7—esophageal cancer	0.00142	0.00292	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CCND1—esophageal cancer	0.00141	0.00291	CbGpPWpGaD
Fluocinolone Acetonide—Malnutrition—Methotrexate—esophageal cancer	0.00141	0.00416	CcSEcCtD
Fluocinolone Acetonide—Erythema—Methotrexate—esophageal cancer	0.00141	0.00416	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00141	0.00416	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Methotrexate—esophageal cancer	0.00138	0.00408	CcSEcCtD
Fluocinolone Acetonide—Prednisolone—ABCB1—esophageal cancer	0.00138	0.0228	CrCbGaD
Fluocinolone Acetonide—Back pain—Methotrexate—esophageal cancer	0.00137	0.00403	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.00136	0.0028	CbGpPWpGaD
Fluocinolone Acetonide—Betamethasone—ABCB1—esophageal cancer	0.00135	0.0223	CrCbGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NR1I2—esophageal cancer	0.00135	0.00277	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00134	0.00394	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Cisplatin—esophageal cancer	0.00134	0.00394	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GDI2—esophageal cancer	0.00133	0.00274	CbGpPWpGaD
Fluocinolone Acetonide—Vision blurred—Methotrexate—esophageal cancer	0.00133	0.00392	CcSEcCtD
Fluocinolone Acetonide—Rash—Cisplatin—esophageal cancer	0.00132	0.0039	CcSEcCtD
Fluocinolone Acetonide—Pain—Capecitabine—esophageal cancer	0.00132	0.0039	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Cisplatin—esophageal cancer	0.00132	0.0039	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—EP300—esophageal cancer	0.0013	0.00268	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Methotrexate—esophageal cancer	0.00127	0.00374	CcSEcCtD
Fluocinolone Acetonide—Nausea—Cisplatin—esophageal cancer	0.00125	0.00368	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00123	0.00254	CbGpPWpGaD
Fluocinolone Acetonide—Cough—Methotrexate—esophageal cancer	0.00123	0.00363	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Capecitabine—esophageal cancer	0.00122	0.00361	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.00122	0.00251	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.00122	0.0025	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.00121	0.00249	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—SLC52A3—esophageal cancer	0.00121	0.00249	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—BLVRB—esophageal cancer	0.00121	0.00249	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—esophageal cancer	0.00121	0.00248	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Methotrexate—esophageal cancer	0.0012	0.00354	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—RB1—esophageal cancer	0.00116	0.00239	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.00116	0.00238	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—HSPA5—esophageal cancer	0.00116	0.00238	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—esophageal cancer	0.00115	0.00236	CbGpPWpGaD
Fluocinolone Acetonide—Infection—Methotrexate—esophageal cancer	0.00115	0.00338	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Capecitabine—esophageal cancer	0.00114	0.00336	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MYC—esophageal cancer	0.00113	0.00233	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Methotrexate—esophageal cancer	0.00113	0.00333	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Capecitabine—esophageal cancer	0.0011	0.00323	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.00108	0.00222	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Capecitabine—esophageal cancer	0.00106	0.00312	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00105	0.0031	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.00104	0.00215	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CA1—esophageal cancer	0.00103	0.00211	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—SLC10A2—esophageal cancer	0.00103	0.00211	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Capecitabine—esophageal cancer	0.00102	0.00302	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.00101	0.00209	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.00101	0.00208	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MYC—esophageal cancer	0.00101	0.00207	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.00101	0.00207	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000995	0.00293	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.000991	0.00204	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Methotrexate—esophageal cancer	0.000986	0.00291	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Capecitabine—esophageal cancer	0.000985	0.0029	CcSEcCtD
Fluocinolone Acetonide—Rash—Capecitabine—esophageal cancer	0.000977	0.00288	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Capecitabine—esophageal cancer	0.000976	0.00288	CcSEcCtD
Fluocinolone Acetonide—Headache—Capecitabine—esophageal cancer	0.00097	0.00286	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KMT2D—esophageal cancer	0.000964	0.00198	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CA2—esophageal cancer	0.00094	0.00193	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—AKAP13—esophageal cancer	0.000937	0.00193	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TP53—esophageal cancer	0.000932	0.00192	CbGpPWpGaD
Fluocinolone Acetonide—Dexamethasone—PTGS2—esophageal cancer	0.000925	0.0153	CrCbGaD
Fluocinolone Acetonide—Nausea—Capecitabine—esophageal cancer	0.00092	0.00271	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000919	0.00189	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Methotrexate—esophageal cancer	0.000912	0.00269	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.000896	0.00184	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PLCE1—esophageal cancer	0.000874	0.0018	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ADH7—esophageal cancer	0.000874	0.0018	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.000867	0.00178	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000864	0.00178	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000859	0.00177	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—ABL1—esophageal cancer	0.000858	0.00176	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PDE4D—esophageal cancer	0.000857	0.00176	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—esophageal cancer	0.000856	0.00176	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—SMG6—esophageal cancer	0.000855	0.00176	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Methotrexate—esophageal cancer	0.00085	0.0025	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000845	0.00174	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CDKN1A—esophageal cancer	0.000834	0.00172	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000825	0.0017	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—esophageal cancer	0.000821	0.00169	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Methotrexate—esophageal cancer	0.000816	0.0024	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GNG7—esophageal cancer	0.000815	0.00168	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PIK3CA—esophageal cancer	0.000791	0.00163	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Methotrexate—esophageal cancer	0.000789	0.00233	CcSEcCtD
Fluocinolone Acetonide—Dexamethasone—ABCB1—esophageal cancer	0.000786	0.013	CrCbGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—WWOX—esophageal cancer	0.000786	0.00162	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ADH1B—esophageal cancer	0.000766	0.00158	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Methotrexate—esophageal cancer	0.000763	0.00225	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.000758	0.00156	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—FKBP1A—esophageal cancer	0.000747	0.00154	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Methotrexate—esophageal cancer	0.000733	0.00216	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TYMP—esophageal cancer	0.000732	0.00151	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—WIF1—esophageal cancer	0.000731	0.0015	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Methotrexate—esophageal cancer	0.000727	0.00214	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Methotrexate—esophageal cancer	0.000726	0.00214	CcSEcCtD
Fluocinolone Acetonide—Headache—Methotrexate—esophageal cancer	0.000722	0.00213	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000718	0.00148	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CXCL2—esophageal cancer	0.000718	0.00148	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP26A1—esophageal cancer	0.000712	0.00147	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000703	0.00145	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ALOX15—esophageal cancer	0.000694	0.00143	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000686	0.00141	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Methotrexate—esophageal cancer	0.000685	0.00202	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000674	0.00139	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—ANXA1—esophageal cancer	0.000668	0.00137	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TPI1—esophageal cancer	0.000662	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTO1—esophageal cancer	0.000662	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—SST—esophageal cancer	0.00065	0.00134	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NR1I2—esophageal cancer	0.000648	0.00133	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000637	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ALDOB—esophageal cancer	0.000635	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GHRL—esophageal cancer	0.000633	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PFN1—esophageal cancer	0.000631	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—NOS2—esophageal cancer	0.000618	0.00127	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GAPDH—esophageal cancer	0.000611	0.00126	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.00061	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CRABP1—esophageal cancer	0.000606	0.00125	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.00059	0.00121	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GNG7—esophageal cancer	0.000576	0.00119	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ELMO1—esophageal cancer	0.000566	0.00117	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—HIST1H2BM—esophageal cancer	0.000556	0.00114	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CREBBP—esophageal cancer	0.000555	0.00114	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—AKAP13—esophageal cancer	0.000554	0.00114	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000543	0.00112	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ALDH2—esophageal cancer	0.00054	0.00111	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTT1—esophageal cancer	0.000513	0.00106	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000511	0.00105	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP2A6—esophageal cancer	0.000507	0.00104	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PDE4D—esophageal cancer	0.000506	0.00104	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000506	0.00104	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—NOS3—esophageal cancer	0.000497	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GNG7—esophageal cancer	0.000482	0.000991	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ENO1—esophageal cancer	0.000481	0.00099	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTGS1—esophageal cancer	0.000481	0.00099	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PSME2—esophageal cancer	0.000474	0.000975	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PSME1—esophageal cancer	0.000474	0.000975	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000469	0.000965	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—XIAP—esophageal cancer	0.000451	0.000929	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PSME1—esophageal cancer	0.000431	0.000887	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PSME2—esophageal cancer	0.000431	0.000887	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CTNNA1—esophageal cancer	0.000427	0.000878	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000426	0.000875	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CXCL2—esophageal cancer	0.000424	0.000873	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000414	0.000852	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP1B1—esophageal cancer	0.000409	0.000842	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NOTCH3—esophageal cancer	0.000407	0.000837	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PSME2—esophageal cancer	0.000396	0.000815	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PSME1—esophageal cancer	0.000396	0.000815	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ANXA1—esophageal cancer	0.000395	0.000812	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP19A1—esophageal cancer	0.000385	0.000791	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SST—esophageal cancer	0.000384	0.000789	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—EP300—esophageal cancer	0.000378	0.000778	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GHRL—esophageal cancer	0.000374	0.000769	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NOTCH3—esophageal cancer	0.000374	0.000769	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—FBXW7—esophageal cancer	0.000368	0.000757	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NOTCH2—esophageal cancer	0.000365	0.000751	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—HMOX1—esophageal cancer	0.000351	0.000722	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000344	0.000708	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ABCB1—esophageal cancer	0.000337	0.000693	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NOTCH2—esophageal cancer	0.000335	0.00069	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—SMAD4—esophageal cancer	0.000307	0.000631	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TGFBR2—esophageal cancer	0.000298	0.000612	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SMAD4—esophageal cancer	0.000282	0.000579	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PIK3CA—esophageal cancer	0.00028	0.000576	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TP53—esophageal cancer	0.000271	0.000557	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000255	0.000524	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MYC—esophageal cancer	0.000253	0.00052	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HIF1A—esophageal cancer	0.00023	0.000474	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NOTCH1—esophageal cancer	0.000226	0.000465	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CREBBP—esophageal cancer	0.000225	0.000463	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KDR—esophageal cancer	0.00022	0.000453	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NOTCH1—esophageal cancer	0.000208	0.000427	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—CREBBP—esophageal cancer	0.000205	0.000421	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NOS3—esophageal cancer	0.000202	0.000415	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CREBBP—esophageal cancer	0.000188	0.000387	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—EGFR—esophageal cancer	0.000185	0.000381	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTGS2—esophageal cancer	0.000184	0.000379	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NOS3—esophageal cancer	0.000169	0.000347	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PIK3CA—esophageal cancer	0.000161	0.00033	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ERBB2—esophageal cancer	0.000158	0.000324	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—EP300—esophageal cancer	0.000153	0.000315	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCND1—esophageal cancer	0.000139	0.000287	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CDKN1A—esophageal cancer	0.000135	0.000277	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EP300—esophageal cancer	0.000128	0.000264	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MYC—esophageal cancer	0.000122	0.00025	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PIK3CA—esophageal cancer	0.000113	0.000233	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MYC—esophageal cancer	0.000112	0.00023	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EGFR—esophageal cancer	0.000109	0.000225	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PIK3CA—esophageal cancer	9.48e-05	0.000195	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TP53—esophageal cancer	9.18e-05	0.000189	CbGpPWpGaD
